On June 17, Novo Nordisk rose 3.31% in pre-market trading, trading at $45.06/share, with turnover of $5.48 million.

The move was driven by Novo Nordisk's global CEO Mike Doustdar announcing during his first visit to China since taking the role that the company plans to submit clinical data for its oral version of Wegovy to Chinese regulators within months, seeking marketing approval for the weight-loss pill. The CEO stated the company aims to catch up with Eli Lilly, which submitted a marketing application for its oral obesity drug in China late last year.

Doustdar also indicated that Novo Nordisk expects generic semaglutide competition to emerge beginning in Q2 2027, noting that while the semaglutide patent expired in China in March, the company retains regulatory data protection through early next year. He further signaled that BD deals in China would increase, stating the company is in active dialogue with multiple Chinese firms. Separately, oral Wegovy recently received UK regulatory approval as the first European market, with clinical data showing 13.6% average weight loss after 64 weeks.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)